We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

94 hedge funds and large institutions have $435M invested in Avadel Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

278% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 9

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

32% more funds holding

Funds holding: 71 → 94 (+23)

31% more capital invested

Capital invested by funds: $332M → $435M (+$103M)

41% less call options, than puts

Call options by funds: $910K | Put options by funds: $1.53M

Holders
94
Holders Change
+23
Holders Change %
+32.39%
% of All Funds
2.51%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
34
Increased
30
Reduced
19
Closed
9
Calls
$910K
Puts
$1.53M
Net Calls
-$625K
Net Calls Change
-$1.47M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.51M
2
CM
Castleark Management
Illinois
+$8.52M
3
Millennium Management
Millennium Management
New York
+$6.58M
4
BFA
BlackRock Fund Advisors
California
+$6.32M
5
MACM
March Altus Capital Management
Connecticut
+$5.64M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$18.3M
2
CCP
Clough Capital Partners
Massachusetts
-$12.7M
3
PC
PointState Capital
New York
-$5.72M
4
TI
Turner Investments
Pennsylvania
-$3.62M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$3.57M +$2.97M +207,915 +29,161%
OM
27
Opaleye Management
Massachusetts
$3.51M +$2.93M +205,000 New
PCM
28
Penn Capital Management
Pennsylvania
$3.5M +$2.92M +204,297 New
CS
29
Candriam SCA
Luxembourg
$3.29M +$2.74M +192,000 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.96M -$496K -34,733 -17%
Comerica Bank
31
Comerica Bank
Texas
$2.79M +$1.4M +97,771 +150%
B
32
Bailard
California
$2.31M -$1.43M -100,000 -43%
RFC
33
Russell Frank Company
Washington
$2.21M +$1.84M +128,743 New
LCG
34
Lisanti Capital Growth
New York
$2.12M -$238K -16,669 -12%
CIP
35
Chartwell Investment Partners
Pennsylvania
$2.07M +$1.72M +120,707 New
WSA
36
Wall Street Associates
California
$1.94M -$106K -7,421 -6%
CCI
37
Columbus Circle Investors
$1.93M +$1.61M +112,492 New
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$1.9M +$251K +17,600 +16%
GOCM
39
Green Owl Capital Management
New York
$1.88M +$1.56M +109,500 New
JGC
40
J. Goldman & Co
New York
$1.77M +$1.47M +103,125 New
Fidelity Investments
41
Fidelity Investments
Massachusetts
$1.71M -$3.3M -230,780 -70%
HCMT
42
Highland Capital Management (Texas)
Texas
$1.7M +$1.42M +99,500 New
ACM
43
Atika Capital Management
New York
$1.59M +$443K +31,000 +50%
IMS
44
Index Management Solutions
Pennsylvania
$1.09M +$164K +11,456 +22%
Janney Montgomery Scott
45
Janney Montgomery Scott
Pennsylvania
$1.08M +$306K +21,455 +52%
TD Asset Management
46
TD Asset Management
Ontario, Canada
$821K +$430K +30,100 +169%
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$798K +$468K +32,757 +237%
COPPSERS
48
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$795K +$8.28K +580 +1%
UBS Group
49
UBS Group
Switzerland
$757K +$631K +44,174 New
OPPM
50
Opus Point Partners Management
New York
$716K +$597K +41,788 New
1
2
3 4 5

AVDL Hedge Fund Activity: Q4 2014 in Review

94 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2014, worth a combined $435M — up 31% from $332M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new AVDL positions and 9 closed out — a net gain of 25 holders — while 30 added to existing stakes and 19 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $9.51M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $18.3M sold.

  • 94 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2014, up from 71 in Q3 2014.
  • Funds reported $435M of Avadel Pharmaceuticals stock for Q4 2014, up 31% quarter-over-quarter.
  • 34 funds opened new Avadel Pharmaceuticals positions in Q4 2014 and 9 closed out, a net change of +25 holders.
  • The largest Avadel Pharmaceuticals buyer in Q4 2014 was T. Rowe Price Associates, an estimated $9.51M added.
  • The largest Avadel Pharmaceuticals seller in Q4 2014 was JP Morgan Chase, an estimated $18.3M sold.

Based on aggregated 13F filings for Q4 2014.